Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;9(2):231-235.
doi: 10.14283/jpad.2022.29.

Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report

S Gauthier  1 , A Boxer, D Knopman, J Sims, R Doody, P Aisen, T Iwatsubo, R Bateman, B Vellas
Affiliations

Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report

S Gauthier et al. J Prev Alzheimers Dis. 2022.

Abstract

There was consensus that both amyloid and tau pathologies should be targeted in Alzheimer's disease, as well as additional pathophysiological mechanisms such as neuroinflammation. The selection of one or both of these targets may depend upon a personalized approach that takes into account the genetic and acquired factors that cause AD in any given person as well as their stage of disease as reflected in a biomarker profile. The validation of this therapeutic approach will be made possible by new methodologies for subdividing into predominant pathology, by efficient methods for identifying people in the earliest stages of disease, and by combination studies.

Keywords: Alzheimer disease; Amyloid; tau; therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

The Task Force was partially funded by registration fees from industrial participants. These corporations placed no restrictions on this work. Dr. Gauthier is a member of scientific advisory boards with Advantage Therapeutics, Alzheon, Amyriad Therapeutics, Biogen Canada, Cerveau Technologies, Lundbeck, TauRx, Dr. Knopman serves on a Data Safety Monitoring Board for the DIAN study. He served on a Data Safety monitoring Board for a tau therapeutic for Biogen but received no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. He has served as a consultant for Roche, Samus Therapeutics, Magellan Health and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH. Dr. Boxer has served as a consultant and/or SAB member for Alector, Arkuda, Arvinas, AZTherapeutics, Denali, GSK, Humana, Oligomerix, Ono, Oscotec, Roche, Stealth, Transposon, True Binding and Wave. He receives research support from Biogen, Eisai, Regeneron, the NIH, Tau Consortium, Bluefield Project, Association for Frontotemporal Degeneration, Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation. * Grant Support: NIH U19AG063911, U54NS092089, R01AG038791, U01AG045390, Tau Research Consortium, Bluefield Project to Cure FTD, University of California Cures AD Program, Association for Frontotemporal Degeneration, CBD Solutions, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Association, UCSF Parkinson’s Spectrum Disorders Center; * Industry research support (funding): Biogen, Eisai, Regeneron; Industry research support (unfunded collaborations); Biogen, Eli Lilly, Novartis. - Industry consulting: AGTC, Alector, Arkuda, Arvinas, AZTherapeutics, GSK, Lundbeck, Oligomerix, Ono, Roche, Samumed, Stealth, Third Rock, Transposon, Wave; Dr. Aisen reports grants from Janssen, Eli Lilly, Eisai, NIA, the Alzheimer’s Association, and FNIH; and consulting fees from Biogen, Roche, Merck, Abbvie, Lundbeck, Proclara, and Immunobrain Checkpoint. He is one of JPAD EiC with no personal compensation. Dr. Sims is employee of Eli Lilly. Dr. Doody is a full-time employee of Genentech, Inc. and F. Hoffmann-La Roche Ltd. Dr. Iwatsubo has nothing to disclose related to this article. Dr. Bateman is Director of DIAN–TU and Principal Investigator of DIAN–TU­001. He receives research support from the NIA of the NIH, DIAN–TU trial pharmaceutical partners (Eli Lilly and Company, F. Hoffman­La Roche Ltd and Avid Radiopharmaceuticals), Alzheimer’s Association, GHR Foundation, Anonymous Organization, DIAN–TU Pharma Consortium (active: Biogen, Eisai, Eli Lilly and Company, Janssen, F. Hoffmann­La Roche Ltd/Genentech; previous: AbbVie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, United Neuroscience). He has been an invited speaker and consultant for AC Immune, F. Hoffman­La Roche Ltd and Janssen and a consultant for Amgen and Eisai. D.H., the Department Head of Neurology where the research is being conducted, is an inventor on patents for solanezumab, currently being tested in the DIAN–TU clinical trials. If solanezumab is approved as a treatment for AD or dominantly inherited AD, Washington University and D.H. will receive part of the net sales of solanezumab from Eli Lilly and Company, which has licensed patents related to solanezumab from Washington University. Dr. Vellas is an investigator in clinical trials sponsored by Biogen, Lilly, Roche, Eisai Pharmaceuticals and the Toulouse University Hospital. He has served as SAB member for Biogen , Alzheon, Green Valey, Norvo Nordisk, Longeveron, but received no personal compensation. He has served as consultant and/or SAB member for Roche, Lilly, Eisai, TauX with personal compensation. He is member of the Editorial Board of JPAD with no personal compensation; and did not have a role in the editorial process/review for this manuscript.

Comment in

LinkOut - more resources